Covid-Vaccinated May Require Lifelong Medication to Prevent Future Heart Attacks, Study Warns

June 20, 2025

307

People who received Covid mRNA “vaccines” may require long-term or lifelong medications to prevent the risk of a deadly heart attack in the future, scientists are warning.

The alert was issued by a team of leading American researchers from Virginia Commonwealth University (VCU) Pauley Heart Center.

Led by Dr. Michele Marchetta, the researchers sought to investigate the long-term risk from recurrent pericarditis following Covid mRNA injections.

Pericarditis is inflammation of the pericardium, the thin sac surrounding the heart.

Often symptomless, this inflammation prevents the heart from pumping blood.

It can lead to blood clots, strokes, cardiac arrest, heart attacks, and sudden death.

This “difficult-to-treat” condition is a known side effect of mRNA “vaccines.”

The new study presents compelling evidence that post-vaccination pericarditis may persist, relapse, and resist standard therapies.

The findings of the study were published in the International Journal of Cardiology.

To prevent relapses, patients may require escalation to targeted anti-inflammatory agents such as IL-1 inhibitors.

The use of this medication would be required long-term, or even lifelong, to prevent future relapses from triggering a heart attack, or worse.

Between October 2021 and January 2025, Marchetta and colleagues tracked eight patients.

All of the subjects had developed recurrent or incessant pericarditis caused by mRNA injections.

The patients had received either the Pfizer-BioNTech (BNT162b2) or Moderna (mRNA-1273) “vaccines.”

Diagnosis was based on 2015 European Society of Cardiology (ESC) guidelines.

All patients tested negative for acute SARS-CoV-2 infection, confirming a post-vaccination, not post-infectious, onset.

The median age of the group was 56 years, ranging from 17 to 82.

6 had received Pfizer and 2 had received Moderna.

All patients developed chest pain within a median of 14 days post-vaccination.

6 of the patients required emergency hospital visits.

Pericardial effusion was seen in 6 patients; 1 progressed to tamponade.

Six patients who failed to respond to standard care required escalation to IL-1 inhibitors.

This report revealed troubling evidence of patients who experience chronic, debilitating, and relapsing symptoms caused by mRNA “vaccines.”

These findings underscore the importance of early recognition and therapeutic escalation in refractory cases.

Clinicians should remain alert to persistent post-vaccine heart issues, the researchers warn.

Doctors are also urged to consider long-term IL-1 blockade in difficult-to-treat cases.

Further research is needed to understand patient-specific risk factors and to distinguish transient immune activation from pathological inflammatory cycles.